CN101573357B - 吲哚化合物 - Google Patents
吲哚化合物 Download PDFInfo
- Publication number
- CN101573357B CN101573357B CN2007800470664A CN200780047066A CN101573357B CN 101573357 B CN101573357 B CN 101573357B CN 2007800470664 A CN2007800470664 A CN 2007800470664A CN 200780047066 A CN200780047066 A CN 200780047066A CN 101573357 B CN101573357 B CN 101573357B
- Authority
- CN
- China
- Prior art keywords
- compound
- optionally substituted
- alkyl
- group
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 **Nc1c(*)c(*)c(*)c2c1[n]c(*)c2* Chemical compound **Nc1c(*)c(*)c(*)c2c1[n]c(*)c2* 0.000 description 30
- DUORKCMPKRFEQO-DAXSKMNVSA-N C=C/C=C\C(CSC(CNC(c1cc2cccc(NS(c3ccc[s]3)(=O)=O)c2[nH]1)=O)C=O)=C Chemical compound C=C/C=C\C(CSC(CNC(c1cc2cccc(NS(c3ccc[s]3)(=O)=O)c2[nH]1)=O)C=O)=C DUORKCMPKRFEQO-DAXSKMNVSA-N 0.000 description 1
- ZLEGAVURRIYHQJ-UHFFFAOYSA-N CC(C)(C1SC(c2cc(cccc3N(C)S(C4=CCCS4)(=O)=O)c3[nH]2)=N1)O Chemical compound CC(C)(C1SC(c2cc(cccc3N(C)S(C4=CCCS4)(=O)=O)c3[nH]2)=N1)O ZLEGAVURRIYHQJ-UHFFFAOYSA-N 0.000 description 1
- YSXDCLWVPYZAGO-UHFFFAOYSA-N CC(C)N(C1=C2NC(c3ncc(CN4C(CO)CCCC4)[s]3)=CC2=CCC1)S(c1ccc[s]1)(=O)=O Chemical compound CC(C)N(C1=C2NC(c3ncc(CN4C(CO)CCCC4)[s]3)=CC2=CCC1)S(c1ccc[s]1)(=O)=O YSXDCLWVPYZAGO-UHFFFAOYSA-N 0.000 description 1
- QBYCVCJVQLIFDG-UHFFFAOYSA-N CC(C)N(c1c2[nH]c(-c3ncc(CN(C)Cc4cnccc4)[s]3)cc2ccc1)S(c1ccc[s]1)(=O)=O Chemical compound CC(C)N(c1c2[nH]c(-c3ncc(CN(C)Cc4cnccc4)[s]3)cc2ccc1)S(c1ccc[s]1)(=O)=O QBYCVCJVQLIFDG-UHFFFAOYSA-N 0.000 description 1
- OLHYZJLWACSTAJ-UHFFFAOYSA-N CC(CCN1CCOCC1)(CN)SCC1=CCCCC1 Chemical compound CC(CCN1CCOCC1)(CN)SCC1=CCCCC1 OLHYZJLWACSTAJ-UHFFFAOYSA-N 0.000 description 1
- QSEUJJMLBYYGRW-UHFFFAOYSA-N CC(CI)N(c1c2[nH]c(-c3ncc(CN4CCCCC4)[s]3)cc2ccc1)S(c1ccc[s]1)(=O)=O Chemical compound CC(CI)N(c1c2[nH]c(-c3ncc(CN4CCCCC4)[s]3)cc2ccc1)S(c1ccc[s]1)(=O)=O QSEUJJMLBYYGRW-UHFFFAOYSA-N 0.000 description 1
- UTQIWMJANMLHES-NNBQYGFHSA-N CC(CI)N(c1cccc2c1[nH]c(-c1ncc(CN3[C@H](COC)CCC3)[s]1)c2)S(c1ccc[s]1)(=O)=O Chemical compound CC(CI)N(c1cccc2c1[nH]c(-c1ncc(CN3[C@H](COC)CCC3)[s]1)c2)S(c1ccc[s]1)(=O)=O UTQIWMJANMLHES-NNBQYGFHSA-N 0.000 description 1
- GGXAUUFZVHPIOZ-UHFFFAOYSA-N CC(CNC(c1cc2cc(OCCOC)cc(N(C)S(c3ncccc3)=O)c2[nH]1)=O)(C=O)SCc1ccccc1 Chemical compound CC(CNC(c1cc2cc(OCCOC)cc(N(C)S(c3ncccc3)=O)c2[nH]1)=O)(C=O)SCc1ccccc1 GGXAUUFZVHPIOZ-UHFFFAOYSA-N 0.000 description 1
- KGIBXJXRRKKTTM-UHFFFAOYSA-N CC(CS1)C=C1S(N(C)c1cccc2c1[nH]c(-c1ncc(CN3CCCC3)[s]1)c2)(=O)=O Chemical compound CC(CS1)C=C1S(N(C)c1cccc2c1[nH]c(-c1ncc(CN3CCCC3)[s]1)c2)(=O)=O KGIBXJXRRKKTTM-UHFFFAOYSA-N 0.000 description 1
- VSKNIVSRKXEBAT-UHFFFAOYSA-N CC1(CCN(Cc2cnc(-c3cc4cccc5c4[N]3(C)C(CC3)C3CN5S(c3ccc[s]3)(=O)=O)[s]2)CC1)O Chemical compound CC1(CCN(Cc2cnc(-c3cc4cccc5c4[N]3(C)C(CC3)C3CN5S(c3ccc[s]3)(=O)=O)[s]2)CC1)O VSKNIVSRKXEBAT-UHFFFAOYSA-N 0.000 description 1
- LRJJONQKXDJXCM-UHFFFAOYSA-N CC1C(CSC(C[N+]([O-])=O)(CC2)CCN2C(OC(C)(C)C)=O)=CC=CC1 Chemical compound CC1C(CSC(C[N+]([O-])=O)(CC2)CCN2C(OC(C)(C)C)=O)=CC=CC1 LRJJONQKXDJXCM-UHFFFAOYSA-N 0.000 description 1
- VNWTVVDHDCINEC-UHFFFAOYSA-N CCN(CC)Cc1cnc(-c2cc(cccc3N(CC)S(c4ccc[s]4)(=O)=O)c3[nH]2)[s]1 Chemical compound CCN(CC)Cc1cnc(-c2cc(cccc3N(CC)S(c4ccc[s]4)(=O)=O)c3[nH]2)[s]1 VNWTVVDHDCINEC-UHFFFAOYSA-N 0.000 description 1
- UDLZLEWTHCTDRQ-UHFFFAOYSA-N CCN(CC)Cc1cnc(C(C2)Nc3c2cccc3N(C(C)C)S(C2=CCCS2)(=O)=O)[s]1 Chemical compound CCN(CC)Cc1cnc(C(C2)Nc3c2cccc3N(C(C)C)S(C2=CCCS2)(=O)=O)[s]1 UDLZLEWTHCTDRQ-UHFFFAOYSA-N 0.000 description 1
- VCYPNKWPWOLQIF-UHFFFAOYSA-N CCN(c1c(CCCC(c2ncc(CN(CCC3)CC3C(OCC)=O)[s]2)=C2)c2ccc1)S(c1ccc[s]1)(=O)=O Chemical compound CCN(c1c(CCCC(c2ncc(CN(CCC3)CC3C(OCC)=O)[s]2)=C2)c2ccc1)S(c1ccc[s]1)(=O)=O VCYPNKWPWOLQIF-UHFFFAOYSA-N 0.000 description 1
- ORXCRYLENRWHBJ-UHFFFAOYSA-N CCOC(C(Cc1cc(OCCOC)c2)N(C(OC(C)(C)C)=O)c1c2NC1CC1)=O Chemical compound CCOC(C(Cc1cc(OCCOC)c2)N(C(OC(C)(C)C)=O)c1c2NC1CC1)=O ORXCRYLENRWHBJ-UHFFFAOYSA-N 0.000 description 1
- CVCNKTXXRQURPS-UHFFFAOYSA-N CCOC(C(NNC(c1cc2cccc(N(C)S(c3ccc[s]3)(=O)=O)c2[nH]1)=O)=O)=O Chemical compound CCOC(C(NNC(c1cc2cccc(N(C)S(c3ccc[s]3)(=O)=O)c2[nH]1)=O)=O)=O CVCNKTXXRQURPS-UHFFFAOYSA-N 0.000 description 1
- UDRKIUYSMGZQQR-UHFFFAOYSA-N CCOC(CC1SC(c2cc(cccc3N(C)S(c4ncc[s]4)(=O)=O)c3[nH]2)=NC1)=O Chemical compound CCOC(CC1SC(c2cc(cccc3N(C)S(c4ncc[s]4)(=O)=O)c3[nH]2)=NC1)=O UDRKIUYSMGZQQR-UHFFFAOYSA-N 0.000 description 1
- VUHLMSXTUILSKS-UHFFFAOYSA-N CCOC(CC1SC(c2cc3cc(C)cc(N(C)Sc4ccc[s]4)c3[nH]2)=NC1)=O Chemical compound CCOC(CC1SC(c2cc3cc(C)cc(N(C)Sc4ccc[s]4)c3[nH]2)=NC1)=O VUHLMSXTUILSKS-UHFFFAOYSA-N 0.000 description 1
- GSLLGGVEQDWDLI-UHFFFAOYSA-N CCOC(c1cc(c(Cl)ccc2N(C)S(c3ccc[s]3)(=O)=O)c2[n]1COC)=O Chemical compound CCOC(c1cc(c(Cl)ccc2N(C)S(c3ccc[s]3)(=O)=O)c2[n]1COC)=O GSLLGGVEQDWDLI-UHFFFAOYSA-N 0.000 description 1
- NBUSSCDUJFJRNY-UHFFFAOYSA-N CCOC(c1cc(cc(cc2N(C)S(c3ncccc3)(=O)=O)OCCOC)c2[nH]1)=O Chemical compound CCOC(c1cc(cc(cc2N(C)S(c3ncccc3)(=O)=O)OCCOC)c2[nH]1)=O NBUSSCDUJFJRNY-UHFFFAOYSA-N 0.000 description 1
- ONIIJZRAMUUDNG-UHFFFAOYSA-N CCOC(c1cc(cc(cc2NSc3ncccc3)OCCCSC)c2[nH]1)=O Chemical compound CCOC(c1cc(cc(cc2NSc3ncccc3)OCCCSC)c2[nH]1)=O ONIIJZRAMUUDNG-UHFFFAOYSA-N 0.000 description 1
- RXLMEOPIYVUIFI-UHFFFAOYSA-N CCOC(c1cc2cccc(NS(c3ccc[o]3)(=O)=O)c2[n]1COC)=O Chemical compound CCOC(c1cc2cccc(NS(c3ccc[o]3)(=O)=O)c2[n]1COC)=O RXLMEOPIYVUIFI-UHFFFAOYSA-N 0.000 description 1
- PURKOLIECOTKHW-UHFFFAOYSA-N CCOCCN(c1cccc(C2)c1NC2c1ncc(CN(CCC2)CC2O)[s]1)S(c1ccc[s]1)(=O)=O Chemical compound CCOCCN(c1cccc(C2)c1NC2c1ncc(CN(CCC2)CC2O)[s]1)S(c1ccc[s]1)(=O)=O PURKOLIECOTKHW-UHFFFAOYSA-N 0.000 description 1
- YQWZVXUTYUKGQK-UHFFFAOYSA-N CCOCCN(c1cccc2c1[nH]c(-c1ncc(CN(CC3)CCN3C(C)=O)[s]1)c2)S(C1=CCCS1)(=O)=O Chemical compound CCOCCN(c1cccc2c1[nH]c(-c1ncc(CN(CC3)CCN3C(C)=O)[s]1)c2)S(C1=CCCS1)(=O)=O YQWZVXUTYUKGQK-UHFFFAOYSA-N 0.000 description 1
- QRCPRGCETCLAIK-UHFFFAOYSA-N CCOCCN(c1cccc2c1[nH]c(-c1ncc(CN(CCC3)CC3c3ncccc3)[s]1)c2)S(c1ccc[s]1)(=O)=O Chemical compound CCOCCN(c1cccc2c1[nH]c(-c1ncc(CN(CCC3)CC3c3ncccc3)[s]1)c2)S(c1ccc[s]1)(=O)=O QRCPRGCETCLAIK-UHFFFAOYSA-N 0.000 description 1
- PREFIJASXXZBRF-UHFFFAOYSA-N CCOCCN(c1cccc2c1[nH]c(C(C(C)C)=S)c2)S(c1ccc[s]1)(=O)=O Chemical compound CCOCCN(c1cccc2c1[nH]c(C(C(C)C)=S)c2)S(c1ccc[s]1)(=O)=O PREFIJASXXZBRF-UHFFFAOYSA-N 0.000 description 1
- FOZJKEUOSYEENN-UHFFFAOYSA-N CC[O](C)C(c1cc(cc(c(-c2cccnc2S)c2N)OCCCO)c2[nH]1)=O Chemical compound CC[O](C)C(c1cc(cc(c(-c2cccnc2S)c2N)OCCCO)c2[nH]1)=O FOZJKEUOSYEENN-UHFFFAOYSA-N 0.000 description 1
- KDKZOLXNIGDOOB-UHFFFAOYSA-N CN(CCC1SC(c2cc(cccc3N(C)S(c4ccc[s]4)(=O)=O)c3[nH]2)=NC1)CCS(C)(=O)=O Chemical compound CN(CCC1SC(c2cc(cccc3N(C)S(c4ccc[s]4)(=O)=O)c3[nH]2)=NC1)CCS(C)(=O)=O KDKZOLXNIGDOOB-UHFFFAOYSA-N 0.000 description 1
- KJXRESPQVWVNIV-UHFFFAOYSA-N CN(CCOC)C(CC1SC(c2cc(cccc3N(C)S(c4ccc[s]4)(=O)=O)c3[nH]2)=NC1)=O Chemical compound CN(CCOC)C(CC1SC(c2cc(cccc3N(C)S(c4ccc[s]4)(=O)=O)c3[nH]2)=NC1)=O KJXRESPQVWVNIV-UHFFFAOYSA-N 0.000 description 1
- BEYYLQOWGYFPAA-OAHLLOKOSA-N CN(c1c2[nH]c(C3=N[C@H](CO)CS3)cc2cc(OCCOC)c1)S(c1ncccc1)(=O)=O Chemical compound CN(c1c2[nH]c(C3=N[C@H](CO)CS3)cc2cc(OCCOC)c1)S(c1ncccc1)(=O)=O BEYYLQOWGYFPAA-OAHLLOKOSA-N 0.000 description 1
- BWIOSJZRLSJZON-UHFFFAOYSA-N CN(c1cc(OC)cc2c1[nH]c(C1=NCC(CN(CC3)CCS3=O)S1)c2)S(c1ccccn1)(O)=O Chemical compound CN(c1cc(OC)cc2c1[nH]c(C1=NCC(CN(CC3)CCS3=O)S1)c2)S(c1ccccn1)(O)=O BWIOSJZRLSJZON-UHFFFAOYSA-N 0.000 description 1
- DUFKNYKYIDRTSY-UHFFFAOYSA-N CN(c1cc(OCCOC)cc2c1[nH]c(C1=NCC3(CCSCC3)S1)c2)S(c1ncccc1)(=O)=O Chemical compound CN(c1cc(OCCOC)cc2c1[nH]c(C1=NCC3(CCSCC3)S1)c2)S(c1ncccc1)(=O)=O DUFKNYKYIDRTSY-UHFFFAOYSA-N 0.000 description 1
- KQDLJTZTYCITGN-UHFFFAOYSA-N CN(c1cccc2c1[nH]c(-c1ncc(CN3CCCCC3)[s]1)c2)S(c1ccc[s]1)(=O)=O Chemical compound CN(c1cccc2c1[nH]c(-c1ncc(CN3CCCCC3)[s]1)c2)S(c1ccc[s]1)(=O)=O KQDLJTZTYCITGN-UHFFFAOYSA-N 0.000 description 1
- AGFWMKUEJKDKIZ-UHFFFAOYSA-N CN(c1cccc2c1[nH]c(C(N)=S)c2)S(c1ccc[s]1)(=O)=O Chemical compound CN(c1cccc2c1[nH]c(C(N)=S)c2)S(c1ccc[s]1)(=O)=O AGFWMKUEJKDKIZ-UHFFFAOYSA-N 0.000 description 1
- YOEWZMKMHOHORW-UHFFFAOYSA-N CN(c1cccc2c1[nH]c(C1=NCC(C(N3CCN(C)CC3)=O)S1)c2)S(c1ccc[s]1)(=O)=O Chemical compound CN(c1cccc2c1[nH]c(C1=NCC(C(N3CCN(C)CC3)=O)S1)c2)S(c1ccc[s]1)(=O)=O YOEWZMKMHOHORW-UHFFFAOYSA-N 0.000 description 1
- QZQNTJGYJKVJKA-UHFFFAOYSA-N CN(c1cccc2c1[nH]c(C1=NCC(CC(N3CCCC3)=O)S1)c2)S(c1ccc[s]1)(=O)=O Chemical compound CN(c1cccc2c1[nH]c(C1=NCC(CC(N3CCCC3)=O)S1)c2)S(c1ccc[s]1)(=O)=O QZQNTJGYJKVJKA-UHFFFAOYSA-N 0.000 description 1
- WKDSSDNCAPCRTK-UHFFFAOYSA-N CN(c1cccc2c1[nH]c(C1=NCC(CC(NS(C)(=O)=O)=O)S1)c2)S(c1ccc[s]1)(=O)=O Chemical compound CN(c1cccc2c1[nH]c(C1=NCC(CC(NS(C)(=O)=O)=O)S1)c2)S(c1ccc[s]1)(=O)=O WKDSSDNCAPCRTK-UHFFFAOYSA-N 0.000 description 1
- LBOHDNZCAMPPJD-UHFFFAOYSA-N CN(c1cccc2c1[nH]c(C1=NCC(CC(Nc3nnc[nH]3)=O)S1)c2)S(c1ccc[s]1)(=O)=O Chemical compound CN(c1cccc2c1[nH]c(C1=NCC(CC(Nc3nnc[nH]3)=O)S1)c2)S(c1ccc[s]1)(=O)=O LBOHDNZCAMPPJD-UHFFFAOYSA-N 0.000 description 1
- BZPLPYPFZMOCEB-UHFFFAOYSA-N CN(c1cccc2c1[nH]c(C1=NCC(CC3=NN(CCO)CC3)S1)c2)S(c1ccc[s]1)(=O)=O Chemical compound CN(c1cccc2c1[nH]c(C1=NCC(CC3=NN(CCO)CC3)S1)c2)S(c1ccc[s]1)(=O)=O BZPLPYPFZMOCEB-UHFFFAOYSA-N 0.000 description 1
- SOWOQHQSMZJJKA-UHFFFAOYSA-N CN(c1cccc2c1[nH]c(C1=NCC(CCNC3CCSCC3)S1)c2)S(c1ccc[s]1)(=O)=O Chemical compound CN(c1cccc2c1[nH]c(C1=NCC(CCNC3CCSCC3)S1)c2)S(c1ccc[s]1)(=O)=O SOWOQHQSMZJJKA-UHFFFAOYSA-N 0.000 description 1
- HFDLQXXEKPHMMQ-UHFFFAOYSA-O CN(c1cccc2c1[nH]c(C1=NCC(CN(C3)CC3O)S1)c2)[SH+]c1ncccc1 Chemical compound CN(c1cccc2c1[nH]c(C1=NCC(CN(C3)CC3O)S1)c2)[SH+]c1ncccc1 HFDLQXXEKPHMMQ-UHFFFAOYSA-O 0.000 description 1
- ANUNRSIVRWBYKF-UHFFFAOYSA-N CN(c1cccc2c1[nH]c(C1=NCC(CNCCO)S1)c2)S(c1ccccn1)=O Chemical compound CN(c1cccc2c1[nH]c(C1=NCC(CNCCO)S1)c2)S(c1ccccn1)=O ANUNRSIVRWBYKF-UHFFFAOYSA-N 0.000 description 1
- LCLRSHYHZYBSET-UHFFFAOYSA-N CN(c1cccc2c1[nH]c(C1=NCC(CO)S1)c2)Sc1ccccn1 Chemical compound CN(c1cccc2c1[nH]c(C1=NCC(CO)S1)c2)Sc1ccccn1 LCLRSHYHZYBSET-UHFFFAOYSA-N 0.000 description 1
- LQPPFPADNSUQJO-UHFFFAOYSA-N CN(c1cccc2c1[nH]c(C1=NCC3(CCN(CC(OC)=O)CC3)S1)c2)S(c1ccc[s]1)(=O)=O Chemical compound CN(c1cccc2c1[nH]c(C1=NCC3(CCN(CC(OC)=O)CC3)S1)c2)S(c1ccc[s]1)(=O)=O LQPPFPADNSUQJO-UHFFFAOYSA-N 0.000 description 1
- YVDDGXDINVURHZ-UHFFFAOYSA-N CN(c1cccc2c1[nH]c(C1=NCC3(CCN(Cc4ccccc4)CC3)S1)c2)S(c1ccc[s]1)(=O)=O Chemical compound CN(c1cccc2c1[nH]c(C1=NCC3(CCN(Cc4ccccc4)CC3)S1)c2)S(c1ccc[s]1)(=O)=O YVDDGXDINVURHZ-UHFFFAOYSA-N 0.000 description 1
- ZLRJFQMOUHEEMD-UHFFFAOYSA-N CNC(CC1SC(c2cc3cccc(N(C)S(c4ccc[s]4)(=O)=O)c3[nH]2)=NC1)=O Chemical compound CNC(CC1SC(c2cc3cccc(N(C)S(c4ccc[s]4)(=O)=O)c3[nH]2)=NC1)=O ZLRJFQMOUHEEMD-UHFFFAOYSA-N 0.000 description 1
- TYLSPXZTHHJAGB-UHFFFAOYSA-O CNc(c([nH]c(C1=NCC(CN(C(CC2)=O)C2=O)S1)c1)c1cc1)c1-c1cccnc1[SH2+] Chemical compound CNc(c([nH]c(C1=NCC(CN(C(CC2)=O)C2=O)S1)c1)c1cc1)c1-c1cccnc1[SH2+] TYLSPXZTHHJAGB-UHFFFAOYSA-O 0.000 description 1
- RBSJFRYIAQRGHO-UHFFFAOYSA-N CNc1c(-c2cccnc2S)c(OCCOC)cc2c1[nH]c(C1=NCC(CN(C)CCO)S1)c2 Chemical compound CNc1c(-c2cccnc2S)c(OCCOC)cc2c1[nH]c(C1=NCC(CN(C)CCO)S1)c2 RBSJFRYIAQRGHO-UHFFFAOYSA-N 0.000 description 1
- CYEJVDXFJUFKSS-UHFFFAOYSA-O CNc1c2[nH]c(C3=NCC(CNCCC(N)=O)S3)cc2ccc1-c1cccnc1[SH+]OC Chemical compound CNc1c2[nH]c(C3=NCC(CNCCC(N)=O)S3)cc2ccc1-c1cccnc1[SH+]OC CYEJVDXFJUFKSS-UHFFFAOYSA-O 0.000 description 1
- PNGCMFJDPJUSTH-UHFFFAOYSA-N COC(C(CN)S)OC Chemical compound COC(C(CN)S)OC PNGCMFJDPJUSTH-UHFFFAOYSA-N 0.000 description 1
- KMVKLIHKBQOVJJ-UHFFFAOYSA-N COC(C(CNC(c1cc(cc(cc2NSc3ncccc3)OCCCSC)c2[nH]1)=O)SCc1ccccc1)OC Chemical compound COC(C(CNC(c1cc(cc(cc2NSc3ncccc3)OCCCSC)c2[nH]1)=O)SCc1ccccc1)OC KMVKLIHKBQOVJJ-UHFFFAOYSA-N 0.000 description 1
- KYUYKPHSCLPENW-UHFFFAOYSA-N COc1ccccc1S(Nc1cccc2c1[nH]c(C(O)=O)c2)(=O)=O Chemical compound COc1ccccc1S(Nc1cccc2c1[nH]c(C(O)=O)c2)(=O)=O KYUYKPHSCLPENW-UHFFFAOYSA-N 0.000 description 1
- SLZVLKGUZHEDPN-UHFFFAOYSA-N CS(CCCOc(cc1NS(c2ncccc2)(=O)=O)cc2c1[nH]c(C1=NCC(CN3CCSCC3)S1)c2)(=O)=O Chemical compound CS(CCCOc(cc1NS(c2ncccc2)(=O)=O)cc2c1[nH]c(C1=NCC(CN3CCSCC3)S1)c2)(=O)=O SLZVLKGUZHEDPN-UHFFFAOYSA-N 0.000 description 1
- QUPCNAQCVPNGIJ-UHFFFAOYSA-N CS(CCCOc1cc(NS(c2ccccn2)(=O)=O)c2[nH]c(C(NCC(C=O)SCc3ccccc3)=O)cc2c1)(=O)=O Chemical compound CS(CCCOc1cc(NS(c2ccccn2)(=O)=O)c2[nH]c(C(NCC(C=O)SCc3ccccc3)=O)cc2c1)(=O)=O QUPCNAQCVPNGIJ-UHFFFAOYSA-N 0.000 description 1
- RQGNSTOYQJBGCC-JOCHJYFZSA-N C[C@]1(CO)N=C(c2cc(cc(cc3N(C)S(c4ccccn4)(=O)=O)OCCOC)c3[nH]2)SC1 Chemical compound C[C@]1(CO)N=C(c2cc(cc(cc3N(C)S(c4ccccn4)(=O)=O)OCCOC)c3[nH]2)SC1 RQGNSTOYQJBGCC-JOCHJYFZSA-N 0.000 description 1
- KHFIPYJTHDPSRH-UHFFFAOYSA-N Cc(cc1)c(cc(C(NCC(CN2CCOCC2)SCc2ccccc2)=O)[nH]2)c2c1N(C)S(c(cccn1)c1Cl)(=O)=O Chemical compound Cc(cc1)c(cc(C(NCC(CN2CCOCC2)SCc2ccccc2)=O)[nH]2)c2c1N(C)S(c(cccn1)c1Cl)(=O)=O KHFIPYJTHDPSRH-UHFFFAOYSA-N 0.000 description 1
- XCLCOCMAVYDKFT-UHFFFAOYSA-O Cc(cc1N(C)S(c2ccc[s]2)=[OH+])cc2c1[nH]c(C(N)=S)c2 Chemical compound Cc(cc1N(C)S(c2ccc[s]2)=[OH+])cc2c1[nH]c(C(N)=S)c2 XCLCOCMAVYDKFT-UHFFFAOYSA-O 0.000 description 1
- DXFMMVOWWSHQPX-UHFFFAOYSA-N NC(c1cc2cccc(N(CC3CC3)S(c3ccc[s]3)(=O)=O)c2[nH]1)=S Chemical compound NC(c1cc2cccc(N(CC3CC3)S(c3ccc[s]3)(=O)=O)c2[nH]1)=S DXFMMVOWWSHQPX-UHFFFAOYSA-N 0.000 description 1
- CWFBPYUQFAFZMK-UHFFFAOYSA-N NC1=C2NC(C3SC(CN(CC4)CCS4(=O)=O)CN3)=CC2CC(OC(CO)c2cc(S)ncc2)=C1 Chemical compound NC1=C2NC(C3SC(CN(CC4)CCS4(=O)=O)CN3)=CC2CC(OC(CO)c2cc(S)ncc2)=C1 CWFBPYUQFAFZMK-UHFFFAOYSA-N 0.000 description 1
- HYJQWMUBCRPGDS-UHFFFAOYSA-N O=S(c1ncc[s]1)(Cl)=O Chemical compound O=S(c1ncc[s]1)(Cl)=O HYJQWMUBCRPGDS-UHFFFAOYSA-N 0.000 description 1
- URSHFHJTAIGHFU-UHFFFAOYSA-N O=S1CCN(CC2SC(c3cc(cccc4NS(c5ncccc5)(=O)=O)c4[nH]3)=NC2)CC1 Chemical compound O=S1CCN(CC2SC(c3cc(cccc4NS(c5ncccc5)(=O)=O)c4[nH]3)=NC2)CC1 URSHFHJTAIGHFU-UHFFFAOYSA-N 0.000 description 1
- OPBPHPUJWRNFOB-UHFFFAOYSA-N OCCC1SC(c2cc(cccc3NS(c4ccc[s]4)(=O)=O)c3[nH]2)=NC1 Chemical compound OCCC1SC(c2cc(cccc3NS(c4ccc[s]4)(=O)=O)c3[nH]2)=NC1 OPBPHPUJWRNFOB-UHFFFAOYSA-N 0.000 description 1
- WHMDPDGBKYUEMW-UHFFFAOYSA-N Sc1ncccc1 Chemical compound Sc1ncccc1 WHMDPDGBKYUEMW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006285551 | 2006-10-19 | ||
| JP285551/2006 | 2006-10-19 | ||
| PCT/JP2007/070772 WO2008050821A1 (en) | 2006-10-19 | 2007-10-18 | Indole compound |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101573357A CN101573357A (zh) | 2009-11-04 |
| CN101573357B true CN101573357B (zh) | 2013-01-23 |
Family
ID=39010108
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2007800470664A Expired - Fee Related CN101573357B (zh) | 2006-10-19 | 2007-10-18 | 吲哚化合物 |
Country Status (26)
| Country | Link |
|---|---|
| US (4) | US7652133B2 (https=) |
| EP (2) | EP2508524A3 (https=) |
| JP (1) | JP5260507B2 (https=) |
| KR (1) | KR101444486B1 (https=) |
| CN (1) | CN101573357B (https=) |
| AU (1) | AU2007310064B2 (https=) |
| BR (1) | BRPI0717722A2 (https=) |
| CA (1) | CA2666973C (https=) |
| CL (1) | CL2008001017A1 (https=) |
| CR (1) | CR10748A (https=) |
| EC (1) | ECSP099330A (https=) |
| GE (1) | GEP20115241B (https=) |
| IL (1) | IL198154A (https=) |
| MA (1) | MA30890B1 (https=) |
| ME (1) | ME00681B (https=) |
| MX (1) | MX2009003972A (https=) |
| MY (1) | MY158052A (https=) |
| NO (1) | NO20091948L (https=) |
| NZ (1) | NZ576570A (https=) |
| PE (1) | PE20090884A1 (https=) |
| RU (1) | RU2454415C9 (https=) |
| TN (1) | TN2009000129A1 (https=) |
| TW (1) | TWI460176B (https=) |
| UA (1) | UA97257C2 (https=) |
| WO (1) | WO2008050821A1 (https=) |
| ZA (1) | ZA200902585B (https=) |
Families Citing this family (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101511074B1 (ko) * | 2007-04-16 | 2015-04-13 | 애브비 인코포레이티드 | 7-치환된 인돌 Ｍｃｌ-1 억제제 |
| JPWO2008136428A1 (ja) | 2007-04-27 | 2010-07-29 | 武田薬品工業株式会社 | 含窒素５員複素環化合物 |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| CN101801965B (zh) * | 2007-08-17 | 2014-07-30 | 株式会社Lg生命科学 | 作为细胞坏死抑制剂的吲哚化合物 |
| RU2450001C2 (ru) * | 2007-12-20 | 2012-05-10 | Эл Джи Лайф Сайенсиз Лтд. | Активаторы глюкокиназы и фармацевтические композиции, содержащие их в качестве активного ингредиента |
| EP2230238B1 (en) * | 2008-01-04 | 2013-12-11 | LG Life Sciences Ltd. | Indole and indazole derivatives having a cell-, tissue- and organ-preserving effect |
| EP2242745A1 (de) * | 2008-02-07 | 2010-10-27 | Sanofi-Aventis | Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| CN102056924B (zh) | 2008-04-10 | 2014-05-21 | 武田药品工业株式会社 | 稠环化合物及其用途 |
| US8349886B2 (en) * | 2008-04-16 | 2013-01-08 | Takeda Pharmaceutical Company Limited | Nitrogenated 5-membered heterocyclic compound |
| AR072297A1 (es) * | 2008-06-27 | 2010-08-18 | Novartis Ag | Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona. |
| US8288559B2 (en) * | 2008-08-18 | 2012-10-16 | Promega Corporation | Luminogenic compounds and methods to detect cytochrome P450 3A enzymes |
| TW201014850A (en) | 2008-09-25 | 2010-04-16 | Takeda Pharmaceutical | Solid pharmaceutical composition |
| JP5535931B2 (ja) | 2008-10-27 | 2014-07-02 | 武田薬品工業株式会社 | 二環性化合物 |
| EP2371826A4 (en) | 2008-12-29 | 2012-06-27 | Takeda Pharmaceutical | NEW CONNECTION WITH CONDENSED RINGS AND ITS USE |
| EP2448921A4 (en) * | 2009-04-09 | 2013-01-23 | Msd Kk | ARYLINDOLDERIVATE |
| WO2010143733A1 (en) | 2009-06-09 | 2010-12-16 | Takeda Pharmaceutical Company Limited | Novel fused cyclic compound and use thereof |
| EP2460523B1 (en) | 2009-07-28 | 2017-01-04 | Takeda Pharmaceutical Company Limited | Tablet |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| AR080969A1 (es) | 2010-04-27 | 2012-05-23 | Takeda Pharmaceutical | Compuesto biciclico |
| TWI511967B (zh) | 2010-06-16 | 2015-12-11 | Takeda Pharmaceutical | 醯胺化合物之結晶 |
| WO2011159781A2 (en) * | 2010-06-17 | 2011-12-22 | Senomyx, Inc. | Bitter taste modulators |
| WO2011157827A1 (de) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| US20130184272A1 (en) | 2010-09-17 | 2013-07-18 | Takeda Pharmaceutical Company Limited | Diabetes therapeutic agent |
| KR20140001965A (ko) | 2010-11-30 | 2014-01-07 | 다케다 야쿠힌 고교 가부시키가이샤 | 바이시클릭 화합물 |
| WO2012111849A1 (en) | 2011-02-17 | 2012-08-23 | Takeda Pharmaceutical Company Limited | Production method of optically active dihydrobenzofuran derivative |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| US8921576B2 (en) * | 2011-10-19 | 2014-12-30 | Kowa Company, Ltd. | Spiroindoline compound, and medicinal agent comprising same |
| JPWO2013061962A1 (ja) | 2011-10-24 | 2015-04-02 | 武田薬品工業株式会社 | 二環性化合物 |
| EP2802571A1 (en) | 2012-01-12 | 2014-11-19 | Takeda Pharmaceutical Company Limited | Benzimidazole derivatives as mch receptor antagonists |
| US9382188B2 (en) | 2012-02-13 | 2016-07-05 | Takeda Pharmaceutical Company Limited | Aromatic ring compound |
| US9181186B2 (en) | 2012-02-13 | 2015-11-10 | Takeda Pharmaceutical Company Limited | Aromatic ring compound |
| WO2013122260A1 (en) | 2012-02-15 | 2013-08-22 | Takeda Pharmaceutical Company Limited | Tablet |
| JP6106179B2 (ja) | 2012-02-24 | 2017-03-29 | 武田薬品工業株式会社 | 芳香環化合物 |
| CN104350040B (zh) | 2012-03-29 | 2016-06-01 | 武田药品工业株式会社 | 芳环化合物 |
| EP2836482B1 (en) * | 2012-04-10 | 2019-12-25 | The Regents of The University of California | Compositions and methods for treating cancer |
| EP2848621A4 (en) | 2012-05-10 | 2016-06-01 | Takeda Pharmaceutical | AROMATIC RING CONNECTION |
| US9505772B2 (en) | 2012-05-10 | 2016-11-29 | Takeda Pharmaceutical Company Limited | Aromatic ring compound |
| AR092843A1 (es) | 2012-06-05 | 2015-05-06 | Takeda Pharmaceuticals Co | Preparacion solida |
| JP2015127299A (ja) | 2012-07-19 | 2015-07-09 | 武田薬品工業株式会社 | 固形製剤 |
| WO2014085486A2 (en) | 2012-11-30 | 2014-06-05 | Waters Technologies Corporation | Methods and apparatus for the analysis of vitamin d metabolites |
| WO2014142363A1 (en) | 2013-03-14 | 2014-09-18 | Takeda Pharmaceutical Company Limited | Spiro azetidine isoxazole derivatives and their use as sstr5 antagonists |
| US10005720B2 (en) | 2013-04-05 | 2018-06-26 | North Carolina Central University | Compounds useful for the treatment of metabolic disorders and synthesis of the same |
| EP3019487A1 (en) | 2013-07-09 | 2016-05-18 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| PT3031799T (pt) | 2013-08-09 | 2018-07-04 | Takeda Pharmaceuticals Co | Composto aromático |
| EP3037412B1 (en) | 2013-08-22 | 2020-09-30 | LG Chem, Ltd. | Indole amide compound as inhibitor of necrosis |
| JO3442B1 (ar) | 2013-10-07 | 2019-10-20 | Takeda Pharmaceuticals Co | مضادات ذات نوع فرعي من مستقبل سوماتوستاتين 5 (sstr5) |
| US9428470B2 (en) | 2014-02-13 | 2016-08-30 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| US9346776B2 (en) | 2014-02-13 | 2016-05-24 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound |
| CN104098498A (zh) * | 2014-07-30 | 2014-10-15 | 天津市斯芬克司药物研发有限公司 | 一种吲唑类化合物及其制备方法 |
| AR111307A1 (es) | 2017-03-30 | 2019-06-26 | Takeda Pharmaceuticals Co | Derivados de 1,2-dihidroespiro[ciclohexan-1,3-indol] o 1,2-dihidroespiro[ciclohexan-1,3-pirrolo[3,2-b]piridina] como inhibidores de hexakisfosfato quinasa |
| AR111199A1 (es) | 2017-03-31 | 2019-06-12 | Takeda Pharmaceuticals Co | Compuesto aromático agonista de gpr40 |
| JOP20190211A1 (ar) | 2017-03-31 | 2019-09-15 | Takeda Pharmaceuticals Co | ببتيد منشط لمستقبل gip |
| JPWO2018181847A1 (ja) | 2017-03-31 | 2020-03-05 | 武田薬品工業株式会社 | 芳香環化合物 |
| WO2019183577A1 (en) | 2018-03-23 | 2019-09-26 | Carmot Therapeutics, Inc. | Modulators of g-protein coupled receptors |
| EP3650440A4 (en) | 2018-08-27 | 2020-11-25 | Scohia Pharma, Inc. | BENZOIC ESTER COMPOUND |
| EP3856339A1 (en) | 2018-09-24 | 2021-08-04 | Takeda Pharmaceutical Company Limited | Gip receptor agonist peptide compounds and uses thereof |
| JP2022503793A (ja) | 2018-09-24 | 2022-01-12 | 武田薬品工業株式会社 | Ｇｉｐ受容体アゴニストペプチド化合物及びその使用 |
| CN109250963B (zh) * | 2018-09-29 | 2021-07-16 | 福建省昊立建设工程有限公司 | 一种复合增韧混凝土及其制备方法 |
| CN119841865A (zh) | 2020-02-07 | 2025-04-18 | 加舒布鲁姆生物公司 | 杂环glp-1激动剂 |
| AR121650A1 (es) | 2020-03-25 | 2022-06-22 | Takeda Pharmaceuticals Co | Dosificación qd de compuestos peptídicos agonistas del receptor de gip y sus usos |
| EP4126920A2 (en) | 2020-03-25 | 2023-02-08 | Takeda Pharmaceutical Company Limited | Gif receptor agonist peptide compounds and uses thereof |
| CN113563306B (zh) * | 2020-04-28 | 2022-07-01 | 新发药业有限公司 | 一种2-(4-苯氧基苯基)-6-(哌啶-4-)基烟酰胺的制备方法 |
| FI4143183T3 (fi) | 2020-04-29 | 2026-01-07 | Gasherbrum Bio Inc | Heterosyklisiä glp-1-agonisteja |
| IL308392A (en) | 2021-05-13 | 2024-01-01 | Carmot Therapeutics Inc | G protein-coupled receptor modulators |
| CN119137124A (zh) | 2022-03-09 | 2024-12-13 | 加舒布鲁姆生物公司 | 杂环glp-1激动剂 |
| WO2023179542A1 (en) | 2022-03-21 | 2023-09-28 | Gasherbrum Bio , Inc. | 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes |
| WO2023198140A1 (en) | 2022-04-14 | 2023-10-19 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| JP2026501171A (ja) | 2022-12-15 | 2026-01-14 | ガシャーブラム・バイオ・インコーポレイテッド | Ｇｌｐ－１アゴニスト活性を有する化合物の塩および固体形態 |
| JP2026501285A (ja) | 2022-12-22 | 2026-01-14 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環式ｇｌｐ－１アゴニスト |
| CN120693338A (zh) | 2022-12-22 | 2025-09-23 | 加舒布鲁姆生物公司 | 杂环的glp-1激动剂 |
| AU2024222719A1 (en) | 2023-02-16 | 2025-08-21 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| US20250019389A1 (en) | 2023-06-30 | 2025-01-16 | Gasherbrum Bio, Inc. | Heterocyclic agonists |
| WO2025015269A1 (en) | 2023-07-13 | 2025-01-16 | Aconcagua Bio, Inc. | Compounds, compositions, and methods |
| WO2025015268A1 (en) | 2023-07-13 | 2025-01-16 | Aconcagua Bio, Inc. | Modulators of calcitonin receptor and/or amylin receptor activity |
| WO2025045208A1 (en) | 2023-08-31 | 2025-03-06 | Gasherbrum Bio, Inc. | Heteroaryl-heterocycloalkyl-based glp-1 agonists |
| WO2025123039A1 (en) * | 2023-12-08 | 2025-06-12 | Shaman Pharma, LLC | Method for Production of Spiro-Oxindole and Indoxyl Derivatives of Mitragynine |
| WO2025137307A1 (en) | 2023-12-20 | 2025-06-26 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| WO2025154021A1 (en) | 2024-01-19 | 2025-07-24 | Takeda Pharmaceutical Company Limited | Improved gip receptor agonist peptide compounds and uses thereof |
| WO2025154020A1 (en) | 2024-01-19 | 2025-07-24 | Takeda Pharmaceutical Company Limited | Improved gip receptor agonist peptide compounds and uses thereof |
| WO2025171340A1 (en) | 2024-02-08 | 2025-08-14 | Aconcagua Bio, Inc. | The treatment of calcitonin- and/or amylin-receptor associated conditions |
| WO2026041075A1 (en) | 2024-08-21 | 2026-02-26 | Gasherbrum Bio, Inc. | Gpl-1 agonists |
| WO2026051998A1 (en) | 2024-09-04 | 2026-03-12 | Aconcagua Bio, Inc. | Compounds, compositions, and methods |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1114506A (zh) * | 1993-09-10 | 1996-01-03 | 卫材株式会社 | 杂二环磺胺衍生物和磺酸酯衍生物 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2656610B1 (fr) | 1989-12-29 | 1992-05-07 | Sanofi Sa | Derives d'amino-2 phenyl-4 thiazole, leur procede de preparation et leur application therapeutique. |
| JP3545461B2 (ja) * | 1993-09-10 | 2004-07-21 | エーザイ株式会社 | 二環式ヘテロ環含有スルホンアミド誘導体 |
| AU6944296A (en) | 1995-09-13 | 1997-04-01 | Takeda Chemical Industries Ltd. | Benzoxazepine compounds, their production and use as lipid lowering agents |
| EE200000488A (et) * | 1998-02-25 | 2002-02-15 | Genetics Institute, Inc. | Fosfolipaasensüümide inhibiitorid ja farmatseutilised kompositsioonid |
| JP4007743B2 (ja) | 1999-02-26 | 2007-11-14 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 血管新生阻害剤 |
| AR035016A1 (es) | 1999-08-25 | 2004-04-14 | Takeda Chemical Industries Ltd | Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima. |
| GB0003636D0 (en) * | 2000-02-16 | 2000-04-05 | Smithkline Beecham Plc | Novel compounds |
| EP1285651B1 (en) | 2000-04-28 | 2010-09-01 | Takeda Pharmaceutical Company Limited | Melanin concentrating hormone antagonists |
| US7229986B2 (en) | 2000-05-16 | 2007-06-12 | Takeda Pharmaceutical Company Ltd. | Melanin-concentrating hormone antagonist |
| RU2309956C2 (ru) * | 2002-10-03 | 2007-11-10 | Ф.Хоффманн-Ля Рош Аг | Производные индол-3-карбоксамида в качестве активаторов глюкокиназы |
| EP1532980A1 (en) | 2003-11-24 | 2005-05-25 | Novo Nordisk A/S | N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes |
| US7498445B2 (en) * | 2004-05-05 | 2009-03-03 | Renopharm Ltd. | Thiazole-based nitric oxide donors capable of releasing two or more nitric oxide molecules and uses thereof |
| EP1632491A1 (en) * | 2004-08-30 | 2006-03-08 | Laboratorios Del Dr. Esteve, S.A. | Substituted indole compounds and their use as 5-HT6 receptor modulators |
| EP2308839B1 (en) * | 2005-04-20 | 2017-03-01 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compounds |
| WO2007037543A1 (ja) | 2005-09-29 | 2007-04-05 | Banyu Pharmaceutical Co., Ltd. | ビアリールアミド誘導体 |
| AU2006295645B2 (en) | 2005-09-30 | 2011-09-29 | Msd K.K. | 2-heteroaryl-substituted indole derivative |
| UY31292A1 (es) | 2007-08-14 | 2009-03-31 | Imidazoles biciclicos fusionados | |
| PT2188291E (pt) | 2007-08-14 | 2012-12-20 | Bayer Ip Gmbh | Pirimidinas bicíclicas fundidas |
| JP2011500625A (ja) | 2007-10-18 | 2011-01-06 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | トリ置換された１，２，４−トリアゾール |
| JO2784B1 (en) | 2007-10-18 | 2014-03-15 | شركة جانسين فارماسوتيكا ان. في | 5,3,1 - Triazole substitute derivative |
-
2007
- 2007-10-18 US US11/907,929 patent/US7652133B2/en not_active Expired - Fee Related
- 2007-10-18 AU AU2007310064A patent/AU2007310064B2/en not_active Ceased
- 2007-10-18 WO PCT/JP2007/070772 patent/WO2008050821A1/en not_active Ceased
- 2007-10-18 TW TW096138971A patent/TWI460176B/zh not_active IP Right Cessation
- 2007-10-18 NZ NZ576570A patent/NZ576570A/en not_active IP Right Cessation
- 2007-10-18 EP EP12170280A patent/EP2508524A3/en not_active Withdrawn
- 2007-10-18 KR KR1020097010151A patent/KR101444486B1/ko not_active Expired - Fee Related
- 2007-10-18 ZA ZA200902585A patent/ZA200902585B/xx unknown
- 2007-10-18 BR BRPI0717722-4A patent/BRPI0717722A2/pt not_active IP Right Cessation
- 2007-10-18 RU RU2009118602/04A patent/RU2454415C9/ru not_active IP Right Cessation
- 2007-10-18 EP EP07830506A patent/EP2074119A1/en not_active Withdrawn
- 2007-10-18 CA CA2666973A patent/CA2666973C/en not_active Expired - Fee Related
- 2007-10-18 GE GEAP200711259A patent/GEP20115241B/en unknown
- 2007-10-18 MY MYPI20091549A patent/MY158052A/en unknown
- 2007-10-18 MX MX2009003972A patent/MX2009003972A/es active IP Right Grant
- 2007-10-18 UA UAA200904957A patent/UA97257C2/ru unknown
- 2007-10-18 ME MEP-2009-118A patent/ME00681B/me unknown
- 2007-10-18 JP JP2009515658A patent/JP5260507B2/ja not_active Expired - Fee Related
- 2007-10-18 US US12/311,893 patent/US8410087B2/en not_active Expired - Fee Related
- 2007-10-18 CN CN2007800470664A patent/CN101573357B/zh not_active Expired - Fee Related
-
2008
- 2008-04-10 CL CL2008001017A patent/CL2008001017A1/es unknown
- 2008-04-16 PE PE2008000659A patent/PE20090884A1/es not_active Application Discontinuation
-
2009
- 2009-03-19 US US12/382,623 patent/US7718798B2/en not_active Expired - Fee Related
- 2009-03-19 US US12/382,622 patent/US7777047B2/en not_active Expired - Fee Related
- 2009-04-08 TN TNP2009000129A patent/TN2009000129A1/fr unknown
- 2009-04-16 IL IL198154A patent/IL198154A/en not_active IP Right Cessation
- 2009-04-24 CR CR10748A patent/CR10748A/es unknown
- 2009-05-13 MA MA31871A patent/MA30890B1/fr unknown
- 2009-05-14 EC EC2009009330A patent/ECSP099330A/es unknown
- 2009-05-19 NO NO20091948A patent/NO20091948L/no not_active Application Discontinuation
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1114506A (zh) * | 1993-09-10 | 1996-01-03 | 卫材株式会社 | 杂二环磺胺衍生物和磺酸酯衍生物 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101573357B (zh) | 吲哚化合物 | |
| US8957070B2 (en) | Glucokinase activator compounds, methods of activating glucokinase and methods of treating diabetes and obesity | |
| CN104981457B (zh) | 杂环化合物 | |
| US20110301155A1 (en) | Indazole compounds for activating glucokinase | |
| CN102056924B (zh) | 稠环化合物及其用途 | |
| TWI454473B (zh) | 稠環化合物及其用途 | |
| HK1175467A (en) | Indole compound |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130123 Termination date: 20171018 |